Fierce Biotech

Lawmakers probe FDA's new priority voucher program, cite corruption and rushed review concerns

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...
MobiHealthNews

FDA launches mobile version of drug information database

The FDA has launched a free mobile app version of its Drugs@FDA online database that offers consumers information on agency-approved drugs. The new app, called Drugs@FDA Express, is free and currently ...
Fierce Biotech

FDA delays decision on Ascendis' dwarfism prospect by 3 months

The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three ...

NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New ...
South Florida Reporter

FDA Announces Sweeping New Vaccine Approval Rules After Internal Review Flags Child Deaths

FDA demands larger trials, stricter safety proof before vaccines approved — citing internal link between COVID‑19 shots and ...
Lawyer Monthly

New Diabetes Pill And Oral Ozempic Alternatives Under FDA Review

FDA is reviewing a new diabetes pill and oral Ozempic alternatives, raising questions about safety, access, pricing ...

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart ...

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology ...